Recent Advances in Cancer Drug Development and Pharmaceutical Analysis: An In-Depth Review

Received: 05-May-2026 Editor assigned: 07-May-2026 Reviewed: 21-May-2026 Revised: 26-May-2026 Published: 30-May-2026

Introduction

Cancer remains one of the most challenging diseases to treat because of its biological complexity; molecular heterogeneity; and ability to evolve during therapy. Tumours may contain multiple subpopulations of cells with distinct genetic and phenotypic characteristics; resulting in variable treatment responses and the development of drug resistance [1,2].

Over the past few decades; the therapeutic landscape of cancer treatment has expanded from conventional cytotoxic chemotherapy to targeted therapies and immune-based treatments [3–6]. Traditional chemotherapy drugs generally act by interfering with DNA replication; cell division; or other processes required for the proliferation of rapidly dividing cells. However; because these drugs may also affect healthy rapidly dividing tissues; their use is frequently associated with adverse effects [3]. Targeted therapies are designed to inhibit specific molecular pathways involved in tumour growth and survival; thereby offering a more selective therapeutic approach [4,5]. Immunotherapies; including immune checkpoint inhibitors; enhance the ability of the immune system to recognize and eliminate cancer cells [5,6].

Pharmaceutical analysis plays an essential role in the development; formulation; and quality control of anticancer drugs. Analytical methods are used to evaluate drug purity; stability; concentration; and bioavailability. High-performance liquid chromatography (HPLC); liquid chromatography–tandem mass spectrometry (LC–MS/MS); and other mass-spectrometric techniques are widely used to quantify anticancer drugs in pharmaceutical formulations and biological samples [7–11]. Pharmacokinetic and pharmacodynamic studies are also important for understanding drug exposure; dose–response relationships; therapeutic efficacy; and treatment-related toxicity [12,13].

Recent advances in drug delivery systems have further improved the therapeutic potential of anticancer agents. Nanoparticle-based formulations; liposomes; polymeric nanocarriers; and other targeted delivery systems can improve drug stability; enhance bioavailability; promote controlled release; and reduce exposure to healthy tissues [14,15]. Antibody–drug conjugates provide an additional targeted-delivery strategy by linking a cytotoxic agent to an antibody that recognizes a tumour-associated antigen [16].

The increasing use of biomarkers and molecular profiling has strengthened the role of precision medicine in oncology. Predictive biomarkers can help identify patients who are more likely to respond to targeted therapies or immunotherapies; supporting more individualized treatment selection [17–22]. Emerging biomarkers; including radiogenomic markers; may also improve the prediction of immunotherapy response [23].

Despite substantial progress; cancer drug development continues to face several challenges; including treatment resistance; toxicity; high costs; limited accessibility; and regulatory complexity. This review provides an overview of the major classes of cancer drugs; their mechanisms of action; and the pharmaceutical analysis techniques used to assess their quality; safety; and efficacy. It also discusses advances in drug delivery systems; biomarker-guided treatment selection; cancer drug discovery; precision medicine; artificial intelligence; and gene-editing technologies [Table 1].

Table 1: Overview of Cancer Drug Classes and Their Mechanisms of Action.

Types of Cancer Drugs

Cancer drugs can be broadly classified into several categories based on their mechanisms of action and therapeutic applications. The major classes include chemotherapy; targeted therapy; immunotherapy; and hormonal therapy. These treatments may be administered individually or as part of combination regimens; depending on the type of cancer; disease stage; molecular characteristics of the tumour; and patient-specific factors [8,15,12].

Chemotherapy

Chemotherapy involves the use of cytotoxic drugs to destroy cancer cells or inhibit their proliferation. These agents primarily target rapidly dividing cells by interfering with DNA synthesis; DNA replication; or cell division [15]. However; chemotherapy drugs may also damage healthy rapidly dividing cells; which can lead to adverse effects such as nausea; fatigue; hair loss; and immunosuppression [15].

Different classes of chemotherapy drugs act through distinct mechanisms. Alkylating agents damage DNA and prevent cancer cells from reproducing; whereas antimetabolites interfere with DNA and RNA synthesis by mimicking the natural substances required for cell division [15]. Cisplatin forms DNA crosslinks that inhibit replication; while doxorubicin intercalates into DNA and interferes with essential cellular processes. Cyclophosphamide is another commonly used cytotoxic drug that damages DNA and suppresses tumour-cell proliferation [15].

Targeted Therapy

Targeted therapies are designed to inhibit specific molecules; receptors; or signalling pathways involved in cancer-cell growth; survival; and metastasis [8,12]. Compared with conventional chemotherapy; these therapies generally offer greater selectivity because they focus on molecular abnormalities that are more prominent in cancer cells than in healthy cells [12].

The selection of targeted therapy is often guided by biomarker testing and molecular profiling. For example; human epidermal growth factor receptor 2 (HER2) testing helps identify patients with HER2-positive breast cancer who may benefit from trastuzumab. Similarly; the detection of epidermal growth factor receptor (EGFR) mutations in non-small-cell lung cancer can support the selection of EGFR inhibitors such as erlotinib [5,7,25]. Imatinib is another targeted drug that inhibits the BCR-ABL fusion protein associated with chronic myeloid leukaemia [12].

Although targeted therapies may reduce damage to healthy tissues; they can still cause adverse effects; including fatigue; skin reactions; diarrhoea; and liver toxicity. The development of resistance to targeted anticancer drugs also remains an important clinical challenge [22].

Immunotherapy

Immunotherapy enhances the ability of the immune system to recognize and destroy cancer cells. This approach has transformed the treatment of several cancers; including melanoma; non-small-cell lung cancer; and renal-cell carcinoma [8,24].

Immune checkpoint inhibitors are among the most important classes of immunotherapy drugs. Cancer cells can exploit immune-checkpoint pathways to suppress T-cell activity and evade immune detection. Checkpoint inhibitors block these inhibitory signals and restore the antitumour immune response [24]. Pembrolizumab and nivolumab are programmed cell death protein 1 (PD-1) inhibitors used in the treatment of multiple cancer types; while ipilimumab targets cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) [10,24].

The clinical response to immunotherapy can vary considerably among patients. Predictive biomarkers are therefore increasingly used to identify individuals who are more likely to benefit from immune-based treatments [3,4,6]. Although immunotherapy can provide durable responses in some patients; it may also cause immune-related adverse events; including skin reactions; colitis; and other inflammatory or autoimmune complications [10,24].

Hormonal Therapy

Hormonal therapy; also known as endocrine therapy; is primarily used for hormone-sensitive cancers such as breast cancer and prostate cancer. These treatments work by reducing hormone production or blocking the interaction between hormones and their receptors on cancer cells [15].

In hormone-receptor-positive breast cancer; tamoxifen blocks the activity of oestrogen receptors; while aromatase inhibitors such as anastrozole reduce oestrogen production. In prostate cancer; androgen-deprivation therapies such as leuprolide reduce testosterone levels; thereby limiting hormone-dependent tumour growth [15].

Hormonal therapies are generally more selective than conventional chemotherapy; but they can still cause adverse effects. Depending on the treatment; these may include hot flashes; changes in mood; reduced bone density; and an increased risk of blood clots [15] [Table 2].

Table 2: Comparison of the Major Classes of Cancer Drugs.

The availability of multiple drug classes has enabled clinicians to select therapies according to the biological and molecular characteristics of each cancer. The growing use of biomarkers and molecular profiling further supports the transition from generalized treatment strategies towards more personalized cancer care [5;7;23;25].

Pharmaceutical Analysis of Cancer Drugs

Pharmaceutical analysis is essential throughout the development of anticancer drugs because it helps establish their identity; purity; stability; safety; and therapeutic performance. Analytical studies are conducted during preclinical development; clinical evaluation; formulation development; manufacturing; and quality control. These studies support the selection of suitable doses; routes of administration; and treatment regimens.

Pharmacokinetic and Pharmacodynamic Evaluation

Pharmacokinetic (PK) analysis describes how a drug is absorbed; distributed; metabolized; and eliminated from the body. Pharmacodynamic (PD) analysis evaluates the relationship between drug exposure and biological or therapeutic response. Together; PK and PD studies help researchers identify an appropriate dose; understand treatment-related toxicity; and optimize therapeutic efficacy [10,20].

The PK profile of an anticancer drug may be influenced by its formulation; route of administration; metabolism; and interactions with other medicines. Monitoring drug concentrations in biological samples can therefore help determine whether adequate drug exposure is achieved while minimizing the risk of toxicity [10,16,20].

Bioavailability and Stability Assessment

Bioavailability testing evaluates the rate and extent to which an active drug reaches systemic circulation. This is particularly important when comparing formulations or developing oral; sustained-release; or targeted-delivery systems. Stability studies assess whether the drug maintains its chemical integrity; potency; and quality during storage and use.

Analytical methods are used to detect drug degradation; quantify impurities; and evaluate formulation performance. These studies are necessary to ensure that anticancer drugs remain safe; effective; and consistent throughout their shelf life [1,2].

High-Performance Liquid Chromatography

High-performance liquid chromatography (HPLC) is one of the most widely used techniques for the analysis of anticancer drugs. It separates the components of a sample and enables the identification and quantification of active pharmaceutical ingredients; impurities; metabolites; and degradation products [1,2,16].

HPLC methods are commonly applied to pharmaceutical formulations and biological samples such as plasma; serum; and urine. These methods support drug-purity testing; stability studies; bioavailability assessment; and pharmacokinetic monitoring [1,2,16].

The reliability of an HPLC method depends on proper validation. Important validation parameters include accuracy; precision; specificity; linearity; sensitivity; recovery; and robustness. A validated method ensures that analytical results are reproducible and suitable for their intended purpose [2,13].

Mass Spectrometry and LC–MS/MS

Mass spectrometry (MS) is a highly sensitive analytical technique used to identify drug molecules and measure their concentrations in complex samples. It is particularly valuable when anticancer drugs or their metabolites are present at very low levels in biological matrices [14,26].

Liquid chromatography–tandem mass spectrometry (LC–MS/MS) combines chromatographic separation with sensitive mass-based detection. This technique is widely used in bioanalytical method development; pharmacokinetic studies; therapeutic drug monitoring; and the quantification of anticancer drugs in plasma; urine; and tissue samples [13,14].

LC–MS/MS is especially useful when high selectivity and sensitivity are required. However; careful method validation is necessary to minimize matrix effects; ensure accurate recovery; and maintain reproducibility [13,14,26].

Spectroscopic Techniques

Spectroscopic techniques are also used to characterize anticancer drugs and evaluate their quality. Ultraviolet-visible (UV–Vis) spectroscopy can be used for quantitative analysis when a drug absorbs light at a suitable wavelength. Infrared (IR) spectroscopy provides information about functional groups; while nuclear magnetic resonance (NMR) spectroscopy supports structural identification and characterization.

These techniques may be used alone or in combination with chromatographic and mass-spectrometric methods. Their applications include identity testing; purity assessment; structural confirmation; and the detection of degradation-related changes [26].

Quality Control and Regulatory Requirements

Quality control is necessary to ensure that anticancer drugs are consistently manufactured according to defined standards. Tests may evaluate the identity; potency; purity; sterility; stability; and dosage accuracy of a pharmaceutical product. These assessments are especially important for anticancer drugs because incorrect dosing or contamination can have serious clinical consequences.

Regulatory review requires evidence that medicines meet appropriate standards of quality; safety; and efficacy before they are approved for clinical use. Analytical data also support post-approval monitoring and the consistent manufacture of pharmaceutical products [15].

Biomarker Analysis in Cancer Therapy

Biomarker analysis has become increasingly important in oncology because it helps identify patients who are more likely to respond to a specific therapy. Molecular and protein-based biomarkers can support diagnosis; prognosis; treatment selection; and the monitoring of therapeutic response [5,7,25].

For example; testing for epidermal growth factor receptor (EGFR) mutations can help identify patients with non-small-cell lung cancer who may benefit from EGFR-targeted treatments such as erlotinib. Human epidermal growth factor receptor 2 (HER2) testing can help identify patients with HER2-positive breast cancer who may benefit from trastuzumab [5,7,25].

Several laboratory techniques are used for biomarker analysis. Polymerase chain reaction (PCR) can detect specific genetic alterations; immunohistochemistry (IHC) can evaluate protein expression in tissue samples; and gene sequencing can identify mutations relevant to targeted treatment selection [5,7,25] [Table 3].

Table 3: Key Pharmaceutical Analysis Techniques Used for Cancer Drugs.

The integration of pharmaceutical analysis with biomarker testing has strengthened the development of safer and more personalized anticancer therapies. Analytical methods not only ensure the quality and consistency of drug products but also help clinicians select treatments that are more appropriate for the molecular characteristics of an individual patient’s tumour.

Drug Delivery Systems in Cancer Treatment

The development of effective drug-delivery systems is an important area of cancer research. Conventional anticancer drugs may circulate throughout the body and affect both tumour cells and healthy tissues; contributing to systemic toxicity and treatment-related adverse effects. Advanced delivery systems aim to improve the therapeutic performance of anticancer agents by enhancing drug stability; increasing bioavailability; enabling controlled release; and improving delivery to tumour tissues [17,19].

Drug-delivery strategies can also help address limitations such as poor aqueous solubility; rapid degradation; short circulation time; and non-specific drug distribution. By modifying the way an anticancer drug is transported and released; researchers aim to increase drug concentrations at the tumour site while reducing exposure to healthy tissues [17,19].

Nanoparticle-Based Drug Delivery

Nanoparticle-based drug-delivery systems are designed to carry anticancer agents and improve their transport to tumour tissues. These systems can protect drugs from premature degradation; improve solubility; and support controlled or sustained drug release [17,19].

Nanoparticles can be produced using different materials; including lipids; polymers; and other biocompatible substances. Their physicochemical properties; such as size; surface characteristics; and composition; can be modified to improve circulation time and influence drug distribution [17,19].

Some nanoparticle-based systems rely on passive accumulation in tumour tissues; while others are designed for active targeting. In active targeting; the surface of a nanoparticle may be modified with molecules that recognize specific receptors or antigens expressed on cancer cells [17,19]. This approach can improve selectivity and reduce off-target effects.

Liposomes

Liposomes are spherical vesicles composed of lipid bilayers. They can encapsulate anticancer drugs and protect them from degradation during circulation. Liposomal formulations can also modify drug distribution and reduce exposure to healthy tissues [17,19].

A well-known example is liposomal doxorubicin; marketed as Doxil. Encapsulation of doxorubicin in liposomes alters its pharmacokinetic profile and helps reduce some of the toxic effects associated with conventional doxorubicin treatment [17,19].

Liposomes can also be modified with targeting molecules to improve their interaction with tumour cells. These modifications may enhance selective delivery and support controlled drug release at the desired site [17,19].

Micelles

Micelles are nanoscale structures formed from amphiphilic molecules. They contain a hydrophobic core and a hydrophilic outer surface. This structure allows micelles to encapsulate poorly water-soluble drugs and improve their apparent solubility [17,19].

Micellar formulations are particularly useful for hydrophobic anticancer agents. By improving solubility and drug transport; micelles can enhance formulation performance and potentially improve bioavailability [17;19]. Genexol-PM; a paclitaxel-loaded polymeric micelle formulation; is an example of this type of delivery system.

Polymeric Nanocarriers

Polymeric nanocarriers are prepared using natural or synthetic polymers. These systems can be designed to carry anticancer drugs and release them gradually over time. Biodegradable polymers are particularly useful because they can break down into smaller components after drug release [17,19].

Poly(lactic-co-glycolic acid); commonly known as PLGA; is frequently investigated as a biodegradable polymer for nanoparticle-based delivery. Polymeric nanocarriers can improve drug stability; support sustained release; and provide opportunities for tumour-targeted delivery [17,19].

Antibody–Drug Conjugates

Antibody–drug conjugates (ADCs) combine the targeting ability of a monoclonal antibody with the cytotoxic activity of an anticancer drug. The antibody component recognizes a specific antigen expressed on cancer cells. After binding to the target antigen; the ADC is internalized; allowing the cytotoxic agent to be released within or near the tumour cell [11].

This approach aims to deliver a potent cytotoxic drug more selectively to cancer cells while reducing systemic exposure. Trastuzumab emtansine; also known as Kadcyla; is an example of an ADC used in the treatment of HER2-positive breast cancer [11].

The effectiveness of an ADC depends on several factors; including antigen selection; antibody specificity; linker stability; and the potency of the cytotoxic payload [11].

Targeted Drug Delivery

Targeted drug delivery can be classified into passive and active approaches. Passive targeting is influenced by the physicochemical characteristics of the delivery system and the properties of tumour tissues. Active targeting involves the use of ligands; antibodies; or other surface-modifying molecules that recognize specific markers on tumour cells [17,19].

Targeted delivery systems can improve drug localization and reduce non-specific distribution. However; their clinical performance may vary because tumours are heterogeneous and may differ in vascular structure; antigen expression; and microenvironmental conditions [17,19,21].

Challenges Associated With Drug-Delivery Systems

Despite considerable progress; several limitations affect the development and clinical application of advanced drug-delivery systems. Tumour heterogeneity can result in uneven drug distribution and variable treatment responses. The tumour microenvironment may also influence the penetration; retention; and activity of anticancer drugs [21].

The blood–brain barrier presents an additional challenge in the treatment of certain brain tumours because it restricts the entry of many therapeutic agents into the central nervous system [17,19]. Other concerns include formulation stability; large-scale manufacturing; reproducibility; safety evaluation; and regulatory approval.

Further research is required to improve the consistency; selectivity; and clinical translation of advanced delivery systems. The development of reliable analytical methods is also essential for evaluating particle size; drug loading; release profiles; stability; purity; and biological performance [Table 4].

Table 4: Overview of Advanced Drug-Delivery Systems for Cancer Treatment.

Advanced drug-delivery systems have the potential to improve the safety and efficacy of anticancer therapies. Nanoparticles; liposomes; micelles; polymeric nanocarriers; and ADCs offer different strategies for improving drug transport and release. However; further research is needed to overcome biological; manufacturing; and regulatory challenges and to ensure that these technologies provide consistent benefits in clinical practice [11,17,19,21].

Challenges Associated With Drug-Delivery Systems

Cancer-drug discovery has evolved considerably with advances in molecular biology; genomic analysis; biotechnology; and pharmaceutical research. Earlier treatment strategies largely relied on cytotoxic drugs; whereas newer approaches increasingly focus on the molecular characteristics of tumours and the identification of therapies that act on specific biological targets [8,9,12,23].

Molecular Profiling and Genetic Analysis

Molecular profiling involves the analysis of genetic mutations; alterations in gene expression; and other tumour-specific characteristics. These investigations help researchers identify the molecular pathways that contribute to cancer-cell growth; survival; and resistance to treatment [5,7,23,25].

The identification of clinically relevant mutations has supported the development of targeted therapies. For example; epidermal growth factor receptor (EGFR) mutations in non-small-cell lung cancer can help identify patients who may benefit from EGFR inhibitors such as erlotinib and gefitinib [7,12,25]. Similarly; human epidermal growth factor receptor 2 (HER2) testing can help identify patients with HER2-positive breast cancer who may respond to trastuzumab [5,7,25].

Biomarker testing also contributes to treatment selection; prognosis assessment; and the monitoring of therapeutic response [5,7,25]. As molecular testing becomes more widely integrated into clinical practice; it is supporting the transition from generalized treatment strategies towards more individualized cancer care [23].

Targeted Therapies

Targeted therapies are designed to inhibit specific receptors; proteins; enzymes; or signalling pathways that contribute to tumour growth and survival [8,12]. These drugs differ from conventional chemotherapy because they focus on molecular abnormalities associated with cancer cells.

Examples include trastuzumab; which targets HER2-positive breast cancer; and imatinib; which inhibits the BCR-ABL fusion protein associated with chronic myeloid leukaemia [12]. EGFR inhibitors such as erlotinib and gefitinib are used in selected patients with EGFR-mutated non-small-cell lung cancer [7,12,25].

Although targeted therapies can improve treatment selectivity; resistance may develop through mechanisms such as mutations in the drug target; activation of alternative signalling pathways; and changes in the tumour microenvironment [21,22]. Understanding these resistance mechanisms is important for the development of combination therapies and next-generation targeted agents.

Immunotherapy

Immunotherapy has transformed the treatment of several cancers by enhancing the ability of the immune system to recognize and destroy tumour cells [8,24]. Immune-checkpoint inhibitors are among the most important advances in this area.

Cancer cells can suppress antitumour immune responses by activating inhibitory checkpoint pathways. Immune-checkpoint inhibitors block these signals and restore T-cell activity against cancer cells [24]. Pembrolizumab and nivolumab target the programmed cell death protein 1 (PD-1) pathway; while ipilimumab targets cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) [10,24].

The effectiveness of immunotherapy varies among patients. Predictive biomarkers are therefore being investigated to identify individuals who are more likely to benefit from immune-based treatments [3,4,6]. Biomarkers can also assist with the assessment of treatment response and the detection of resistance [3,4,6,25].

Emerging radiogenomic biomarkers may provide additional information for predicting immunotherapy response by combining imaging characteristics with molecular data [27].

Precision Medicine

Precision medicine aims to tailor cancer treatment according to the molecular profile of an individual patient’s tumour. This approach uses genomic information; biomarker testing; and clinical characteristics to support the selection of therapies that are more likely to be effective [5,7,23,25].

Next-generation sequencing and other molecular-analysis techniques can identify genetic alterations that may be suitable for targeted treatment. Precision medicine can therefore reduce the use of ineffective therapies and limit unnecessary adverse effects [23].

The continued development of validated biomarkers is essential for the successful application of precision medicine. Biomarkers must be reliable; clinically meaningful; and suitable for use in routine practice [5,7,25].

CAR-T Cell Therapy and Emerging Therapeutic Platforms

Chimeric antigen receptor T-cell therapy; commonly known as CAR-T cell therapy; is an important advancement in cancer immunotherapy. In this approach; a patient’s T cells are modified to recognize specific antigens expressed by cancer cells and are then administered back to the patient [18].

CAR-T cell therapy has shown important clinical potential; particularly in selected haematological malignancies [18]. However; its broader application requires continued research into treatment safety; manufacturing complexity; patient selection; and the identification of suitable tumour targets.

Novel therapeutic and functionalization platforms are also being investigated to improve drug targeting and therapeutic performance [9]. These emerging approaches may support the development of more selective and effective cancer treatments.

Artificial Intelligence and Machine Learning

Artificial intelligence (AI) and machine learning (ML) are emerging tools in oncology research. These technologies can assist with the analysis of large and complex datasets; supporting the identification of patterns that may be difficult to detect using conventional analytical approaches.

AI-based models are being evaluated for the prediction of adverse drug reactions in oncology; with the aim of improving treatment safety and supporting clinical decision-making [28]. Further research is needed to establish the reliability; transparency; and clinical applicability of these models.

Challenges in Cancer-Drug Discovery

Despite substantial progress; several challenges continue to affect cancer-drug discovery. Drug resistance remains a major limitation because tumour cells can evolve and develop mechanisms that reduce treatment effectiveness [21,22].

Tumour heterogeneity is another important challenge. Different cell populations within the same tumour may respond differently to a particular therapy; making it difficult to develop a single treatment that is effective for every patient [21].

The development of novel therapies can also be expensive and time-consuming. New anticancer drugs must undergo rigorous preclinical evaluation; clinical testing; and regulatory review before they can be approved for patient use [15]. Ensuring that advanced treatments are affordable and accessible remains an important consideration [Table 5].

Table 5: Key Advances in Cancer-Drug Discovery.

Advances in molecular profiling; targeted therapy; immunotherapy; precision medicine; CAR-T cell therapy; and computational methods are reshaping cancer-drug discovery. Continued research is required to overcome treatment resistance; improve safety; validate biomarkers; and ensure that innovative therapies are accessible to patients.

Challenges in Cancer Drug Development

Despite considerable progress in cancer-drug discovery; the development of effective and widely accessible anticancer therapies remains challenging. Cancer is a biologically complex and heterogeneous disease; and treatment outcomes may vary considerably among patients. Major obstacles include drug resistance; treatment-related toxicity; tumour heterogeneity; high development costs; limited accessibility; and regulatory complexity.

Drug Resistance

Drug resistance is one of the most significant challenges in cancer treatment. A therapy may initially reduce tumour growth but gradually become less effective as cancer cells adapt or evolve. Resistance can occur before treatment begins or develop during therapy.

Cancer cells may become resistant through several mechanisms; including mutations in the drug target; activation of alternative signalling pathways; changes in drug metabolism; increased drug efflux; and alterations in the tumour microenvironment [21,22]. These mechanisms can reduce the concentration or activity of a drug within cancer cells and lead to treatment failure.

Resistance is particularly important in targeted therapy because the selective pressure created by treatment can promote the survival of resistant cell populations [22]. Combination therapies; sequential treatment strategies; and the identification of new molecular targets are being investigated to delay or overcome resistance [21,22].

Toxicity and Adverse Effects

The toxicity of anticancer drugs is another major concern. Conventional chemotherapy affects rapidly dividing cells and may damage both cancer cells and healthy tissues. This can result in adverse effects such as nausea; fatigue; hair loss; and immunosuppression [15].

Targeted therapies and immunotherapies are generally more selective than conventional chemotherapy; but they can still cause clinically significant adverse effects. Immune-checkpoint inhibitors may produce immune-related adverse events because they increase immune-system activity [10,24]. These reactions may affect the skin; gastrointestinal tract; endocrine organs; liver; or other tissues.

Pharmacokinetic and pharmacodynamic studies are important for understanding the relationship between drug exposure; therapeutic response; and toxicity [10,20]. Artificial-intelligence-based approaches are also being investigated as tools for predicting adverse drug reactions in oncology [28].

Tumour Heterogeneity

Tumour heterogeneity refers to the presence of genetically and biologically distinct cancer-cell populations within the same tumour or among different tumour sites in the same patient. These cell populations may respond differently to treatment; making it difficult to identify a single therapy that is effective against every part of the disease [21].

The tumour microenvironment can further influence treatment response. Interactions among cancer cells; immune cells; stromal cells; blood vessels; and signalling molecules may affect drug penetration and contribute to resistance [21].

Molecular profiling and biomarker analysis can help identify clinically relevant tumour characteristics and support more personalized treatment selection [5,7,23,25]. However; tumour characteristics may change over time; particularly after exposure to therapy; creating an ongoing need for treatment monitoring and reassessment.

Tumour Heterogeneity

The effectiveness of an anticancer drug depends not only on its pharmacological activity but also on its ability to reach the tumour site in an adequate concentration. Poor solubility; rapid degradation; non-specific distribution; and limited penetration into tumour tissue can reduce therapeutic performance [17,19].

Nanoparticles; liposomes; polymeric carriers; and other advanced delivery systems are being developed to improve drug stability; bioavailability; and targeted delivery [17,19]. Antibody–drug conjugates provide an additional strategy by linking a cytotoxic drug to an antibody that recognizes a tumour-associated antigen [11].

Despite their potential; advanced drug-delivery systems face challenges related to formulation stability; reproducibility; manufacturing complexity; safety assessment; and clinical translation. Biological barriers; including the blood–brain barrier; can also limit the delivery of anticancer agents to certain tumour sites [17,19].

High Costs and Limited Accessibility

The discovery and development of new anticancer therapies require extensive laboratory research; preclinical evaluation; clinical trials; manufacturing processes; and regulatory review. These activities contribute to the complexity and cost of bringing new therapies into clinical practice [15].

Personalized treatments may also require molecular profiling; biomarker testing; specialized laboratory facilities; and trained personnel [5;23;25]. These requirements can create challenges when attempting to implement precision medicine across different healthcare settings.

Improving accessibility requires collaboration among researchers; healthcare providers; regulatory authorities; manufacturers; and policymakers. Strategies may include more efficient development pathways; wider access to diagnostic testing; and efforts to improve the affordability of effective treatments.

Biomarker Validation

Biomarkers are increasingly used to guide the selection of targeted therapies and immunotherapies. However; a biomarker must be analytically reliable and clinically meaningful before it can be used routinely in treatment decisions [3–7,25].

Predictive biomarkers can help identify patients who are more likely to respond to a specific therapy; while prognostic biomarkers provide information about the likely course of the disease [5,7,25]. Biomarkers may also support the monitoring of treatment response and the early detection of relapse.

The validation of biomarkers can be difficult because tumours are heterogeneous and biomarker expression may vary among patients or change during therapy. Emerging approaches; including radiogenomic biomarkers; may provide additional tools for predicting treatment response [27].

Regulatory Challenges

Anticancer drugs must undergo rigorous evaluation before they are approved for clinical use. Regulatory authorities assess the quality; safety; efficacy; manufacturing consistency; and risk–benefit profile of a new treatment [15].

The evaluation of novel therapies may be particularly complex when the treatment involves advanced drug-delivery systems; antibody–drug conjugates; cell-based treatments; gene-editing technologies; or combination regimens. These products may require specialized methods for quality control; safety assessment; and long-term monitoring.

Regulatory pathways must balance the need for timely access to promising treatments with the requirement to protect patient safety. Reliable pharmaceutical analysis; validated biomarkers; and carefully designed clinical trials are essential for achieving this balance [Table 6].

Table 6: Major Challenges in Cancer-Drug Development.

Addressing these challenges requires a multidisciplinary approach. Continued research into resistance mechanisms; safer therapies; validated biomarkers; improved drug-delivery systems; and efficient regulatory pathways will be essential for the development of more effective and accessible cancer treatments.

Future Directions in Cancer Drug Development

The future of cancer-drug development is increasingly focused on personalized treatment; biomarker-guided therapy selection; immunotherapy expansion; advanced drug-delivery systems; and the use of computational tools in oncology research. Continued progress in these areas may improve treatment selectivity; reduce toxicity; and support more effective clinical decision-making.

Precision Medicine and Genomic Profiling

Precision medicine aims to tailor cancer treatment according to the molecular characteristics of an individual patient’s tumour. Biomarker testing and genomic profiling can help identify clinically relevant mutations and support the selection of therapies that are more likely to be effective [5,7,23,25].

The increasing use of next-generation sequencing can improve the detection of genetic alterations associated with tumour growth; treatment response; and resistance. These molecular data can guide the selection of targeted therapies and reduce the unnecessary use of treatments that are unlikely to benefit a particular patient [7,23,25].

The successful implementation of precision medicine depends on the availability of reliable biomarkers; validated laboratory methods; and access to appropriate diagnostic facilities [5,7,25]. Further research is also required to determine how changes in tumour biology during treatment should influence subsequent therapeutic decisions.

Expansion of Immunotherapy

Immunotherapy is expected to remain a major area of cancer-drug development. Immune-checkpoint inhibitors have already transformed the treatment of several cancers by restoring the ability of immune cells to recognize and attack tumour cells [8,24].

Pembrolizumab and nivolumab target the programmed cell death protein 1 (PD-1) pathway; while ipilimumab targets cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) [10,24]. Future research may expand the use of these agents in additional cancer types and improve the selection of patients who are most likely to benefit.

Predictive biomarkers are increasingly important for identifying patients who may respond to immune-checkpoint inhibitors [3,4,6]. Biomarker-guided treatment selection may improve therapeutic outcomes while reducing unnecessary exposure to ineffective therapies.

Chimeric antigen receptor T-cell therapy; commonly known as CAR-T cell therapy; is another important area of immunotherapy research. CAR-T cell therapies use modified T cells to recognize and attack cancer cells and have demonstrated important clinical potential in selected haematological malignancies [18]. Continued research is needed to improve their safety; manufacturing efficiency; and applicability to a broader range of cancers.

Combination Treatment Strategies

Combination therapies are being investigated to improve treatment effectiveness and overcome drug resistance. Cancer cells may escape treatment through mutations in drug targets; activation of alternative signalling pathways; and changes in the tumour microenvironment [21,22].

Combining targeted therapies; immunotherapies; chemotherapy; or other treatment modalities may help address multiple resistance mechanisms simultaneously. However; combination regimens must be carefully evaluated because they can also increase the risk of toxicity.

Pharmacokinetic and pharmacodynamic studies are essential for optimizing combination therapies. These studies can help determine appropriate doses; treatment schedules; and exposure–response relationships [10,20].

Advanced Drug-Delivery Systems

Advanced drug-delivery systems are expected to play an increasingly important role in cancer treatment. Nanoparticles; liposomes; polymeric nanocarriers; and other delivery systems can improve drug stability; enhance bioavailability; support controlled release; and reduce exposure to healthy tissues [17,19].

Future research will focus on improving the selectivity and clinical performance of these systems. Surface modification with targeting molecules may improve the recognition of tumour-associated markers and enhance drug delivery to cancer cells [17,19].

Antibody–drug conjugates are another promising approach. These therapies combine the targeting properties of a monoclonal antibody with the cytotoxic activity of an anticancer drug [11]. Further development of antibody–drug conjugates will require careful optimization of antigen selection; antibody specificity; linker stability; and payload activity.

Biomarkers for Treatment Selection and Monitoring

Biomarkers will continue to play a central role in the development of personalized cancer therapies. Predictive biomarkers can help identify patients who are more likely to benefit from a specific treatment; while prognostic biomarkers can provide information about disease progression and expected outcomes [5,7,25].

Biomarkers can also support the monitoring of treatment response and the detection of resistance. Their clinical usefulness depends on analytical accuracy; reproducibility; and validation in appropriate patient populations [3–7,25].

Emerging radiogenomic biomarkers may provide additional information by combining imaging features with molecular data. These approaches are being investigated as potential tools for predicting immunotherapy response [27].

Artificial Intelligence and Machine Learning

Artificial intelligence (AI) and machine learning (ML) are emerging tools in oncology research. These technologies can support the analysis of large and complex datasets and may assist with the identification of patterns relevant to cancer treatment.

AI-based models are being investigated for the prediction of adverse drug reactions in oncology [28]. This application may support treatment-safety assessment and improve clinical decision-making. Further research is required to validate these models and ensure that their predictions are reliable; transparent; and clinically useful.

Novel Therapeutic Platforms

Novel therapeutic platforms are being investigated to improve the selectivity and effectiveness of cancer treatment [9]. These approaches may include new targeting strategies; functionalized drug-delivery systems; and emerging biological therapies.

Gene-based and gene-modifying approaches are also areas of ongoing research. However; further preclinical and clinical evidence is required before detailed conclusions can be drawn regarding their routine use in cancer treatment.

Accessibility and Regulatory Considerations

Scientific innovation must be accompanied by efforts to improve treatment accessibility. The development of new anticancer therapies requires extensive preclinical evaluation; clinical testing; manufacturing controls; and regulatory review [15].

Personalized therapies may also require specialized diagnostic methods; biomarker testing; and advanced laboratory infrastructure [5,23,25]. These requirements may limit access in healthcare settings with fewer resources.

Future cancer-drug development should therefore focus not only on therapeutic innovation but also on affordability; scalable manufacturing; reliable quality control; and equitable access. Regulatory pathways must balance timely access to promising treatments with the need to establish safety; efficacy; and manufacturing consistency [15] [Table 7].

Table 7: Future Directions in Cancer-Drug Development.

The future of cancer-drug development will depend on the integration of molecular profiling; validated biomarkers; safer delivery systems; immune-based therapies; and reliable computational tools. Continued collaboration among researchers; clinicians; pharmaceutical scientists; regulatory authorities; and policymakers will be essential for translating scientific advances into effective and accessible treatments.

CONCLUSION

Cancer remains one of the most formidable challenges in modern medicine; but significant strides in drug development over the past few decades have brought hope to millions of patients worldwide. The evolution of cancer therapies from traditional chemotherapy to the more advanced targeted therapies; immunotherapies; and gene-editing technologies has fundamentally transformed the landscape of cancer treatment.

Pharmaceutical analysis plays an essential role in the successful development and application of cancer drugs. By evaluating the pharmacokinetics; pharmacodynamics; and bioavailability of drugs; pharmaceutical scientists ensure that these therapies are both effective and safe for patients. Additionally; the development of advanced drug delivery systems; such as nanoparticles; liposomes; and antibody-drug conjugates; has significantly enhanced the precision and efficacy of cancer treatments; reducing systemic toxicity and improving patient outcomes.

The future of cancer drug development is bright; with precision medicine; immunotherapy; and advanced drug delivery systems leading the way toward more targeted; effective; and personalized cancer therapies. The integration of artificial intelligence and machine learning into the drug discovery process is accelerating the identification of novel cancer drug candidates and optimizing treatment regimens. Meanwhile; gene-editing technologies like CRISPR offer the potential for curative treatments; providing a new avenue for the fight against cancer.

However; challenges such as drug resistance; high treatment costs; and the need for greater accessibility remain significant obstacles. Addressing these issues will require continued innovation; collaboration; and investment in both the scientific and regulatory aspects of cancer drug development. Nonetheless; with ongoing advances in technology and a deeper understanding of cancer biology; the future holds tremendous promise for the development of more effective; less toxic; and more affordable cancer therapies.

The continued focus on personalized treatments and the growing role of immunotherapy provide hope that cancer can eventually be treated as a manageable disease; rather than a terminal one. As research progresses; the future of cancer treatment will undoubtedly be shaped by cutting-edge technologies that offer new hope for millions of patients around the world.

REFERENCES

1. Liu J, et al. Role of tumor microenvironment in drug resistance in cancer. Cancer Research. 2024;84:5312-5324.

   Crossref, Google Scholar

2. Patel V, et al. Mechanisms of resistance to targeted anticancer drugs. Nature Reviews Clinical Oncology. 2024;21:127-141.

   Crossref, Google Scholar

3. National Cancer Institute. Cancer drug development and regulation. 2021.

   Google Scholar

4. Crisci S, Amitrano F, Saggese M, Muto T, Sarno S, et al. Overview of Current Targeted Anti-Cancer Drugs for Therapy in Onco-Hematology. Medicina. 2019;55:414.

   Crossref, Google Scholar, [PubMed]

5. Li MSC, et al. Developments in targeted therapy and immunotherapy for cancer. Cancer Treatment Reviews. 2022;49:40-52.

   Crossref, Google Scholar

6. Smith G, et al. Advances in immunotherapy and checkpoint inhibitors. Journal of Clinical Oncology. 2024;42:945-953.

   Crossref, Google Scholar

7. Van Andel L, et al. Review of chromatographic bioanalytical methods for anticancer drugs. Journal of Pharmaceutical and Biomedical Analysis. 2018;163:80-90.

   Crossref, Google Scholar

8. Sabourian R, et al. HPLC methods for quantifying anticancer drugs in biological samples: A systematic review. Analytical Biochemistry. 2020;601:1-12.

   Crossref, Google Scholar

9. Sahithi A, et al. Bioanalytical method development and validation of anticancer drugs by LC-MS/MS. Journal of Analytical Chemistry. 2023;75:470-482.

   Crossref, Google Scholar

10. Wong ALA, et al. Liquid chromatography–tandem mass spectrometry in anticancer drug quantification. Journal of Pharmaceutical and Biomedical Analysis. 2018;163:55-65.

    Crossref, Google Scholar

11. White K, et al. Advanced mass spectrometry techniques in anticancer drug analysis. Mass Spectrometry Reviews. 2023;42:512-527.

    Crossref, Google Scholar

12. Le Louedec F, et al. Cancer immunotherapy dosing and pharmacokinetics review. Frontiers in Oncology. 2020;10:645-656.

    Crossref, Google Scholar

13. Chen D, et al. Pharmacokinetic–pharmacodynamic models in oncology drug development. Clinical Pharmacology & Therapeutics. 2025;98:210-225.

    Crossref, Google Scholar

14. Grieco P, et al. Advances in nanoparticle-based targeted drug delivery systems for cancer. Frontiers in Medicine. 2024;11:125-136.

    Crossref, Google Scholar

15. Zhang L, et al. Nanoparticle drug delivery strategies in cancer therapy. Advanced Drug Delivery Reviews. 2024;175:31-45.

    Crossref, Google Scholar

16. Tarighi P, et al. Optimizing cancer treatment: Antibody-drug conjugates and targeted delivery. European Journal of Pharmaceutical Sciences. 2025;95:99-108.

    Crossref, Google Scholar

17. Puntambekar M, et al. Predictive biomarkers in cancer immunotherapy: A narrative review. Cancer Treatment Reviews. 2025;50:123-130.

    Crossref, Google Scholar

18. Mihaila RI, et al. Importance of predictive biomarkers for immune checkpoint inhibitors. Journal for ImmunoTherapy of Cancer. 2024;12:140-150.

    Crossref, Google Scholar

19. AlDoughaim M, et al. Cancer biomarkers and precision oncology: A review of advances. Cancers. 2024;16:141-155.

    Crossref, Google Scholar

20. Imyanitov EN, et al. Overview on biomarkers for immune oncology drugs. Cancer Treatment Reviews. 2025;58:142-154.

    Crossref, Google Scholar

21. Zhou Y, et al. Tumor biomarkers for diagnosis, prognosis and targeted therapies. Signal Transduction and Targeted Therapy. 2024;9:97-109.

    Crossref, Google Scholar

22. Garcia D, et al. Clinical applications of biomarkers in oncology drug development. Cancer Metastasis Reviews. 2023;42:59-71.

    Crossref, Google Scholar

23. Tan SY, et al. Emerging radiogenomic biomarkers in immunotherapy response prediction. Radiology. 2024;292:512-523.

    Crossref, Google Scholar